Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 7Lymphoid 5Gynecologic 5Other solid neoplasm 4Head & Neck 4Genitourinary 4Other hematologic neoplasm 3Breast 3Thoracic 2Dermatologic 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other neoplasm 1Myeloid 1

Conditions

Small Cell Lung Carcinoma 2Recurrence 1Lung Neoplasms 1

Interventions

Carboplatin 1174Cisplatin 891Pemetrexed 847pembrolizumab 626Paclitaxel 609Docetaxel 539Gemcitabine 428Radiotherapy 393Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 297durvalumab 264Drug Therapy 260osimertinib 237atezolizumab 225Radiosurgery 196Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 132Ipilimumab 129130-nm albumin-bound paclitaxel 125Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Fenretinide × Thoracic × Clear all
NCT06922539 2025-12-15

ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

SciTech Development, Inc.

Phase 1 Recruiting
44 enrolled
Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT00009971 2013-02-11

Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
32 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡